Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors

doi:10.21203/rs.3.rs-3174557/v1

This phase Ib study was performed to determine the safety, the maximal tolerated dose (MTD), and recommended phase II dose (RP2D) of capecitabine with alpleisib in patients with advanced solid tumors. Regardless of PIK3CA mutation, patients were administered orally once daily alpelisib (200mg and 300mg) and twice daily capecitabine (850mg/m², 1,000mg/m², 1,250mg/m², days 1–14) every 3 weeks. Standard “3+3” dose escalation was used to define the MTD. The effect of alpelisib on the PK of capecitabine was assessed. Patients with 6 colorectal cancer (three PIK3CA mutation) and 6 breast cancer (all PIK3CA mutation) were enrolled. The first three patients in dose level 0 (alpelisib 200mg, capecitabine 1,000 mg/m²) had no dose-limiting toxicities (DLTs). In dose level 1 (alpelisib increased to 300 mg), one of six patients had DLT (grade 3 hyperglycemia). At dose level 2 (capecitabine 1,250 mg/m²), no patients had DLTs, establishing it as the MTD/RP2D. The most common AE was grade 1-3 hyperglycemia (75.0%). Antitumor activity was observed in patients with PIK3CA mutant breast cancer (3 partial response and 3 stable disease). Alpelisib was unaffected by capecitabine (C_max and AUC_0-12). This combination is generally tolerated, and shows antitumor activity in patients with PIK3CA mutant advanced cancers.

Health sciences/Oncology/Cancer

Health sciences/Diseases/Cancer/Cancer therapy

Metastatic cancer

Alpelisib

Capecitabine

PIK3CA mutation

The phosphoinositide 3-kinase (PI3K) pathway is frequently altered in human cancer, reported at a rate of nearly 30% in solid cancer ^1–3. Aberrant activation of this pathway is associated with cancer cell proliferation, cell survival, and angiogenesis ^4–6. The PIK3CA gene(the phosphatidylinositol-4,5bisphosphate 3-kinase catalytic subunit alpha gene) is the most frequently altered PI3K isoform in solid tumors, with gain-of-function mutations upregulating downstream AKT-mTOR signaling pathways that promote cancer cell growth and proliferation ^7,8. Alpelisib, an oral selective inhibitor of class I PI3K p110α ^9,10, has demonstrated antitumor properties in preclinical studies, particularly in the PIK3CA-mutated cancer models ¹⁰. In a first-in-human phase I study with advanced solid malignancies with PIK3CA alterations, alpelisib showed encouraging preliminary activity and a tolerable safety profile, with the MTD declared as 400 mg once daily ¹¹. However, the clinical efficacy of single-agent alpelisib has been limited, suggesting that combination therapy may be more effective. Alpelisib has been combined with multiple anticancer drugs, such as fulvestrant ^12,13, everolimus ¹⁴, olaparib ¹⁵, encorafenib ¹⁶, paclitaxel ¹⁷, cisplatin ¹⁸, and cetuximab ¹⁹. Based on the results of the SOLAR-1 trial, alpelisib has been approved in combination with the fulvestrant for the treatment of PIK3CA-mutated, HR(hormone receptor)-positive, HER2(human epidermal growth factor receptor 2)-negative advanced breast cancer who had received endocrine therapy previously ¹². Currently, Alpelisib is being studied in different combinations, expecting to improve synergy effects and overcome resistance to chemotherapy.

Capecitabine is an oral prodrug of 5-FU(fluorouracil) that is effective as chemotherapy treatment for multiple cancers, including colorectal ^20,21, gastric ²², pancreatic ²³, and breast cancer ²⁴. As a monotherapy, it has been widely used for salvage regimens in Korea based on retrospective data with a moderate disease control rate of 60% ²⁵. Capecitabine has demonstrated safety and anti-tumor activity when used in combination with other chemotherapy or biological agents such as bevacizumab and lapatinib ^26,27. Additionally, the combination of capecitabine with an mTOR inhibitor targeting the PI3K/AKT/mTOR signaling pathway has shown antitumor effects and tolerable safety^28,29. Preclinical data has also suggested that combining PI3K inhibition with 5-fluorouracil could increase the anticancer effects in cancer cell lines³⁰.

In this phase I trial, we evaluated the combination of capecitabine and alpelisib in patients with advanced solid cancer to determine its safety, tolerability, and pharmacokinetic interaction. This phase I trial aimed to assess whether this combination therapy would be a feasible and effective treatment option, especially for patients with PIK3CA mutant tumors.

Patient characteristics.

Between February 2021, and August 2021, we enrolled 12 patients with advanced solid tumors from Korea University Anam Hospital in Korea and received escalating doses of alpelisib and capecitabine. The median age of enrolled patients was 53.7 years old (range, 33-69) and median number of prior systemic therapies was 3.5 (range, 2-14). 6 patients had colorectal cancer, and 6 patients had breast cancer (including 9 patients with confirmed PIK3CA mutation, 3 colorectal cancer, and 6 breast cancer). At the time of data cutoff (April 2023), three patients with breast cancer remained on treatment, with a median follow-up of 3 months (1-26.5 months). (Table 1).

Dose Escalation and Dose-Limiting Toxicities.

The first three patients in dose level 0 (alpelisib 200mg daily, capecitabine 1000 mg/m² twice daily) had no dose-limiting toxicities (DLTs). In dose level 1 (alpelisib increased to 300 mg daily, capecitabine 1000mg twice daily), one of six patients had DLT (grade (Gr) 3 hyperglycemia). When dose level 2 (alpelisib 300mg daily, capecitabine 1250 mg/m² twice daily) was expanded to 3 patients, no patients had DLTs. The combination of alpelisib 300mg daily and capecitabine 1250 mg/m² twice daily was declared the MTD/RP2D in patients with advanced solid tumors.

Efficacy.

The overall objective response rate (ORR) was 25.0% (3 of 12 patients), and the disease control rate (DCR) was 50.0% (6 of 12 patients). Three patients had a partial response, and three had stable disease. The median duration of response in patients with a partial response was 12.5 months (range, 3.5-26.5). The median PFS was 5.9 months (range 0.9-26.5), and the median OS was 9.7 months. At the time of the data cutoff, nine patients died, and three patients survived. The duration of treatment varied depending on the type of cancer. Colorectal cancer patients received almost two cycles of treatment, but breast cancer patients received a median of 14.8 cycles of treatment. Therefore, antitumor activity was observed in patients with PIK3CA mutant breast cancer (3 partial response and 3 stable disease of a total of 6 patients). (Table 2)

Safety.

Treatment-related AEs occurred in 100.0% (any grade) and 33.3% (Grade 3) of patients. No Grade 4-5 treatment-related AEs occurred. The most frequently reported all-grade, non-hematologic AEs included Gr 2-3 nausea (75.0%), Gr 1-2 diarrhea (50.0%), Gr 1-2 hand-foot syndrome (41.7%), Gr 1-2 anorexia (41.7%), Gr 2 mucositis (33.3%). The most common all-grade, non-hematologic AEs were Gr 1-3 hyperglycemia (75.0%, 9 of 12 patients), and sequentially Gr 1-3 hyperbilirubinemia (50.0%), Gr 1-2 anemia (33.3%).

The Gr 3 treatment-related AEs were nausea (33.3%, 4 of 12 patients), hyperglycemia (16.7%, 2 of 12 patients), hyperbilirubinemia (16.7%), weakness, and gallbladder perforation (all 8.3%). Remarkably, hyperglycemia was dominantly observed in patients with colorectal cancer, with Gr 3 hyperglycemia reported in all 2 colorectal cancer patients. All-grade hyperglycemia was present in all colorectal cancer patients and in 50% of breast cancer patients. (Table 3)

Pharmacokinetics

The pharmacokinetics of alpelisib and capecitabine were evaluated in this study (Fig. 1, Table 4). The mean peak plasma concentrations (C_max) of alpelisib at dose levels 0, 1, and 2 were 1,167.8 ng/mL, 1,235.3 ng/mL, and 2,035.6 ng/mL, respectively, with a time to reach peak concentration (t_max) of 2-4 hours. The area under the concentration-time-curve (AUC) of alpelisib increased with dose escalation, ranging from 4,930.5 ng·h/mL to 8,192.2 ng·h/mL. The half-life of alpelisib was longer at dose level 1 (9.29 hours) compared to dose level 0 (6.5 hours) and dose level 2 (4.3 hours).

For capecitabine, the mean C_max at dose levels 0, 1, and 2 were 2,498.0 ng/mL, 4,159.0 ng/mL, and 7,004.5 ng/mL, respectively, with a t_maxof 1-2 hours. The AUC of capecitabine increased with dose escalation, ranging from 2,674.4 ng·h/mL to 8,710.8 ng·h/mL. The half-life of capecitabine was shortest at dose level 1 (0.63 hours) and longest at dose level 2 (0.73 hours).

Overall, the pharmacokinetics of alpelisib and capecitabine were consistent with previous studies. No pharmacokinetic interactions were observed between the two drugs. However, given the limited sample size and the need for more comprehensive pharmacokinetic analyses, further studies with larger cohorts are needed to provide a better understanding of the effects of dose expansion of the combination therapy.

This phase Ib study explored the safety, MTD, and PR2D of the combination of capecitabine with the oral PIK3CA inhibitor alpelisib in patients with advanced solid tumors refractory to standard therapy. The results showed that the combination treatment was generally well-tolerated and had an acceptable toxicity profile. Only one DLT, which was grade 3 hyperglycemia, was observed in one out of six patients treated at dose level 1. Based on our study's definition, we identified the MTD and RP2D as alpelisib 300 mg daily continuously combined with 1,250 mg/m² capecitabine twice daily for 14 days in 3-weekly cycles. Therefore, we planned further phase II trials to evaluate the efficacy and safety of this combination therapy using the established dosing regimen.

Hyperglycemia was the most commonly reported treatment-related adverse event and the only dose-limiting toxicity observed in our study. Hyperglycemia is a well-known side effect of PI3K-AKT-mTOR pathway inhibitors. The inhibition of this pathway can lead to abrogated insulin function, impaired insulin secretion, and the development of insulin resistance, resulting in hyperglycemia ^2,4,31. Previous studies have reported the incidence of hyperglycemia associated with PI3K-AKT-mTOR pathway inhibitors in large phase III clinical trials ranging from 13 to 63.7% and high-grade hyperglycemia from 4 to 32.7% ^32–34. The incidence of hyperglycemia may also differ depending on the combination drug, disease stage, and alpelisib dose used. For example, in the phase 1b study of triple-combination therapies (encorafenib and cetuximab with alpelisib) in colorectal cancer (BRAF-mutant), the incidence of hyperglycemia was 39.3% ¹⁶, while a phase II study of alpelisib plus fulvestrant in hormone receptor-positive breast cancer resulted in 29% of hyperglycemia ³⁵. In a phase III study (SOLAR-1), hormone receptor-positive breast cancer showed a higher incidence of hyperglycemia at 63.7% ¹². While the frequency of hyperglycemia by cancer type is not well-known in previous clinical studies, it is clear that the severity and incidence of hyperglycemia can vary based on several factors.

In our study, all-grade hyperglycemia was reported in 66.7% (2/3) of patients in the alpelisib 100 mg BID group (dose level 0) and 77.8% (7/9) of patients in the alpelisib 150 mg BID group (dose level 1,2). Grade 3 hyperglycemia was observed in 16.7% (2/12) of patients. The median time to onset of all-grade hyperglycemia was 3.1 weeks (range, 1.0 to 8.7). Although the number of patients was small, there appeared to be a difference in hyperglycemia incidence according to cancer type. Specifically, hyperglycemia was reported in all colon cancer patients and in half of the breast cancer patients. In our study, colon cancer patients appeared to be at a higher risk of hyperglycemia, likely due to the presence of several risk factors such as old age, history of bowel resection, and use of medication that can increase the risk of hyperglycemia. The median age of colon cancer patients was higher than that of breast cancer patients (58.5 years vs. 49.5 years), and all colon cancer patients underwent partial colorectal resection. Furthermore, most colorectal cancer patients were enrolled as third-line chemotherapy. They received FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and FOLFIRI (folinic acid, fluorouracil, and irinotecan)-based chemotherapy in the previous first and second-line treatments, which may have made them more vulnerable to hyperglycemia due to long exposure to dexamethasone with standard pre-medication. Therefore, our findings suggest that clinicians should exercise caution when administering alpelisib and capecitabine to colorectal cancer patients with risk factors for hyperglycemia and closely monitor blood glucose levels during treatment. Further studies are needed to evaluate the safety of this combination therapy using the established dosing regimen.

Other adverse events of combination therapy were nausea, stomatitis, and hand-foot syndrome. The hand-foot syndrome can be attributed to capecitabine since this has not been observed before in single-agent alpelisib trials. This well-known side effect of capecitabine resulted in dose reductions of capecitabine in our patients. The median time to onset of all grade hand-foot syndrome was 6.1 weeks (range, 3.1 to 15.0), as was previously known from the study. Although stomatitis is a common adverse event of both capecitabine and alpelisib as a single agent, this overlapping toxicity remained mild to moderate in severity in this study and was not dose-limiting.

The combination of alpelisib and capecitabine demonstrated sustained clinical activity in some breast cancer patients with PIK3CA mutations. Two patients with breast cancer are still on the study for over 12 months. Median progression-free survival (PFS) of 10.4 months showed promising results in patients with heavily-treated breast cancer. In particular, three patients had more than 10 cycles of treatment and had the following mutations: PIK3CA H1047L, PTEN 317_318del, PTCH1 D898N, CDH1 S649fs; PIK3CA E545K, PIK3CA E726K, CDH1 R598*, AR P549S; and PIK3CA N345K TP53 M237I, respectively, which PIK3CA mutation points were heterogeneousAlthough this studies had small sample size, previous studies have shown that CDH1 mutation might enhance the effectiveness of PIK3CA inhibitors when present together ^36,37.

The combination of alpelisib and capecitabine did not show significant clinical benefits in colorectal cancer patients compared to breast cancer. This suggests that the role of PIK3CA mutation as a driver mutation may vary depending on the cancer types. The median PFS for this treatment was only 1.4 months. This could be due to the absence of PIK3CA mutation in half of colorectal cancer patients, and the frequent co-occurrence of KRAS pathogenic variants with PIK3CA mutations, leading to a shorter reported PFS and potentially reduced activity against PIK3CA inhibitors. Studies have shown that tumors with aberrant activation of the RAS/RAF/MEK/ERK pathway, such as KRAS-mutant cancers, do not respond to PI3K pathway inhibitors ^38–40. One study of tarselicib found that patients with both PIK3CA and KRAS mutations had a lower response rate and shorter progression-free survival compared to those with only a PIK3CA mutation ⁴¹. However, further research is needed to confirm and expand upon these findings.

The results of our study demonstrate that the pharmacokinetics of alpelisib and capecitabine are not affected when these agents are co-administered in patients with advanced cancer. In particular, the C_max and AUC values of both drugs were similar across all dose levels, indicating that there were no pharmacokinetic interactions between alpelisib and capecitabine. Our study also found that the time to reach peak plasma concentration (t_max) was consistent with previous reports of alpelisib and capecitabine. These findings suggest that it is safe to combine these two agents in patients with advanced cancer. Overall, the pharmacokinetic results of our study support the safety and tolerability of the alpelisib-capecitabine combination and provide a basis for further investigation of this combination in larger phase II clinical trials. Additional pharmacokinetic analyses may be useful in these trials to further characterize the pharmacokinetics of alpelisib and capecitabine and to optimize dosing strategies for this combination therapy.

Limitations of this study include the small number of patients, no control groups, and data for a single institution. Although our study has reached several endpoints, definitive conclusions cannot be drawn with respect to the synergistic effects of this combination. Moreover, we currently lack clear biomarkers to predict which patients have long-term responses. In addition, insufficient pharmacokinetics and pharmacodynamic analyses are requested better to understand the effects of dose reduction and discontinuation.

In conclusion, our study demonstrated that the combination of alpelisib 300 mg daily and capecitabine 1,250 mg/m2 twice daily for 14 days in 3-weekly cycles is a safe and well-tolerated treatment option for patients with advanced cancers harboring PIK3CA mutations. Our findings also indicate that this combination therapy achieved prolonged clinical benefits in a significant number of patients. Notably, toxicities associated with this treatment were generally manageable, and no unexplained severe toxicities were reported. Overall, our study suggests that the combination of alpelisib and capecitabine could be a promising treatment option for patients with PIK3CA mutant advanced cancers, and further investigation is needed in phase II trial.

Study design.

This phase Ib, open-label, single-arm study (ClinicalTrials.gov identifier: NCT04753203) enrolled patients with advanced solid tumors using a standard 3 + 3 dose escalation design. The primary objective of a phase Ib was to determine the MTD and RP2D of alpelisib in combination with capecitabine. Secondary objectives included assessment of dose-limiting toxicity (DLT), safety, pharmacokinetics (PK), and preliminary anti-tumor activity of alpelisib plus capecitabine combination. The exploratory objective included biomarker analysis for efficacy and resistance of the alpelisib plus capecitabine combination.

Patients.

The dose-escalation phase Ib enrolled patients with a histologically-confirmed, advanced/recurrent solid tumor who have progressed on standard therapy or whose disease does not have established standard therapy and is not limited to PIK3CA mutation.

Eligibility criteria included: Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤ 1, adequate bone marrow and organ function, and life expectancy of ≥ 3 months. Patients diagnosed with diabetes, impaired glucose tolerance (with a blood glucose of 140–199 mg/dL after a 2-hour oral glucose tolerance test (75g)), previous history of gestational diabetes, or steroid-induced diabetes were not included. The full list of inclusion and exclusion criteria is in Supplement Table 1.

Study treatment.

Patients were administered orally once daily alpelisib (200mg and 300mg) and twice daily capecitabine (850mg, 1000mg, 1250mg orally, days 1–14) every 3 weeks. A total of 4 dose levels (Supplement Table 2) was planned, and a standard “3 + 3” design was applied to define the MTD. The MTD was defined as the highest dose at which DLT was experienced by < 33% of patients in the first treatment cycle. The RP2D was determined according to the MTD in phase Ib.

DLT was defined as treatment-related adverse events (AEs); DLT did not include adverse events associated with the disease (e.g., symptomatic deterioration due to tumor progression). DLT assessment was only performed during the first cycle and was based on NCI-CTCAE (version 5.0). The evaluation period of DLT was 21 days (i.e., one cycle treatment period). In the absence of DLT, a subject was considered evaluable for DLT only if capecitabine was administered all 3 times and alpelisib was administered 75% or more (That is, the completion of taking at least 42 times out of a total of 56 times). DLT included: grade 2 hyperglycemia (FPG > 160–250 mg/dL; confirmed with a repeat FPG within 24 hrs.) that did not resolve to grade 1 or less (< 140 mg/dL) within 21 consecutive days (after initiation of oral anti-diabetic treatment; specified grade ≥ 3 hematologic, renal, hepatic, metabolic, or subcutaneous AEs lasting for 7 days; or any other grade 3 toxicity.

Study assessments.

Efficacy. Efficacy parameters were defined using the RECIST (Response Evaluation Criteria in Solid Tumors), version 1.1. The efficacy end-points were progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), disease control rate (DCR), and overall survival (OS).

Safety. Physical examinations including vital signs, body weight, and ECOG performance status were assessed at screening, every 3 weeks. Adverse events and laboratory safety assessment according to NCI CTCAE version 5.0. Safety was monitored throughout the treatment period by the collection of AEs.

Pharmacokinetics. The pharmacokinetic (PK) analysis was conducted in all patients who received at least one dose of alpelisib and capecitabine combination therapy. Blood samples were collected at specified time points, including pre-dose, 1, 2, 4, and 6 hours post-dose, on day 1 of cycle 1. Measurements of alpelisib and capecitabine were carried out with a validated LC-MS/MS assay. PK parameters, including maximum plasma concentration (C_max), time to reach maximum plasma concentration (t_max), area under the plasma concentration-time curve (AUC), and elimination half-life (t_1/2), were calculated using non-compartmental methods. The PK parameters of alpelisib and capecitabine were analyzed separately, and the effect of dose on PK was evaluated. The data were presented as the mean (range) and standard deviation (SD).

PIK3CA mutational analysis. PIK3CA status was assessed by next-generation sequencing (NGS) using archival or fresh tumor biopsy samples collected before the study started. Specimens were prepared from formalin-fixed and paraffin-embedded tumor tissue. Targeted sequencing was performed using K-MASTER protocol ⁴².

Ethics approval and consent to participate.

The clinical trial was approved by the institutional review boards of all participating institutions (2020AN0539) and by the FDA. All procedures involving human participants were carried out in accordance with the Declaration of Helsinki. Written, informed consent was obtained from patients or guardians before enrolment in the study.

Author contributions

Conceptualization: A.R.L., and S.L.; data acquisition and interpretation: A.R.L., B.K. and J.H.K.; formal analysis: A.R.L., and K.H.P.; data curation: A.R.L., B.K. and K.H.P.; writing—original draft preparation: A.R.L., Y.H.K. and S.L.; writing—review and editing: A.R.L., Y.H.K. and S.L.; supervision: S.L.. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (HI17C2206).

Ethics approval

The study was approved by the Institutional Review Board of Korea University Anam Hospital (2020AN0012). All patients provided written informed consent for this study.

Competing interest

The authors have no relevant financial or non-financial interests to disclose.

Data availability

The data presented in this study are available on request from the author.

Velho, S. et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur. J. Cancer 41, 1649–1654. https://doi.org/10.1016/j.ejca.2005.04.022 (2005).
Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science (1979) 304, 554. https://doi.org/10.1126/science.1096502 (2004).
Millis, S. Z., Ikeda, S., Reddy, S., Gatalica, Z. & Kurzrock, R. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. JAMA Oncol. 2, 1565–1573. https://doi.org/10.1001/jamaoncol.2016.0891 (2016).
Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561–573. https://doi.org/10.1016/j.ccr.2005.05.014 (2005).
Shaw, R. J. & Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430. https://doi.org/10.1038/nature04869 (2006).
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F. & Hirsch, E. PI3K/AKT signaling pathway and cancer: an updated review. Ann. Med. 46, 372–383. https://doi.org/10.3109/07853890.2014.912836 (2014).
Yang, J. et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol. Cancer 18, 26. https://doi.org/10.1186/s12943-019-0954-x (2019).
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. & Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988–1004. https://doi.org/10.1038/nrd1902 (2005).
Furet, P. et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg. Med. Chem. Lett. 23, 3741–3748. https://doi.org/10.1016/j.bmcl.2013.05.007 (2013).
Fritsch, C. et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 13, 1117–1129. https://doi.org/10.1158/1535-7163.Mct-13-0865 (2014).
Juric, D. et al. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J. Clin. Oncol. 36, 1291–1299. https://doi.org/10.1200/jco.2017.72.7107 (2018).
André, F. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N. Engl. J. Med. 380, 1929–1940. https://doi.org/10.1056/NEJMoa1813904 (2019).
Tolaney, S. M. et al. Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR(+) Advanced Breast Cancer. Clin. Cancer Res. 27, 418–428. https://doi.org/10.1158/1078-0432.Ccr-20-0645 (2021).
Curigliano, G. et al. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. Eur. J. Cancer 151, 49–62. https://doi.org/10.1016/j.ejca.2021.03.042 (2021).
Konstantinopoulos, P. A. et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 20, 570–580. https://doi.org/10.1016/s1470-2045(18)30905-7 (2019).
van Geel, R. et al. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov. 7, 610–619. https://doi.org/10.1158/2159-8290.Cd-16-0795 (2017).
Rodon, J. et al. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget 9, 31709–31718. https://doi.org/10.18632/oncotarget.25854 (2018).
Tsang, E. S. et al. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Res. Commun. 2, 570–576. https://doi.org/10.1158/2767-9764.Crc-22-0028 (2022).
Dunn, L. A. et al. A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 106, 564–570. https://doi.org/10.1016/j.ijrobp.2019.09.050 (2020).
Van Cutsem, E. et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 19, 4097–4106. https://doi.org/10.1200/jco.2001.19.21.4097 (2001).
Schüller, J. et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 45, 291–297. https://doi.org/10.1007/s002800050043 (2000).
Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315–321. https://doi.org/10.1016/s0140-6736(11)61873-4 (2012).
Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825. https://doi.org/10.1056/NEJMoa1011923 (2011).
Miller, K. D. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792–799. https://doi.org/10.1200/jco.2005.05.098 (2005).
Kim, S. T. et al. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. Asia Pac. J. Clin. Oncol. 7, 82–87. https://doi.org/10.1111/j.1743-7563.2010.01363.x (2011).
Hegewisch-Becker, S. et al. Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial. J. Clin. Oncol. 29, 1044. https://doi.org/10.1200/jco.2011.29.15_suppl.1044 (2011).
Cameron, D. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 112, 533–543. https://doi.org/10.1007/s10549-007-9885-0 (2008).
Lee, S. J. et al. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest. New Drugs 31, 1580–1586. https://doi.org/10.1007/s10637-013-0022-0 (2013).
Kordes, S. et al. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother. Pharmacol. 75, 1135–1141. https://doi.org/10.1007/s00280-015-2730-y (2015).
Ishida, K. et al. Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil. Sci. Rep. 7, 2262. https://doi.org/10.1038/s41598-017-02548-9 (2017).
Samuels, Y. & Velculescu, V. E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221–1224. https://doi.org/10.4161/cc.3.10.1164 (2004).
Peterson, M. E. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer 21, 2341–2349. https://doi.org/10.1007/s00520-013-1826-3 (2013).
Xu, K. Y., Shameem, R. & Wu, S. Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. Acta Oncol. 55, 1196–1203. https://doi.org/10.3109/0284186x.2016.1168939 (2016).
Burnette, S. E. et al. Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. Breast Cancer Res. Treat. 197, 369–376. https://doi.org/10.1007/s10549-022-06798-8 (2023).
Rugo, H. S. et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 22, 489–498. https://doi.org/10.1016/s1470-2045(21)00034-6 (2021).
Elangovan, A. et al. Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. Mol. Cancer Res. 20, 1405–1419. https://doi.org/10.1158/1541-7786.Mcr-22-0090 (2022).
Khoury, K. et al. Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. Front. Oncol. 10, 1475. https://doi.org/10.3389/fonc.2020.01475 (2020).
Mayer, I. A. et al. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin. Cancer Res. 23, 26–34. https://doi.org/10.1158/1078-0432.Ccr-16-0134 (2017).
Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351–1356. https://doi.org/10.1038/nm.1890 (2008).
Luo, Q. et al. KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report. Transl. Oncol. 13, 100874. https://doi.org/10.1016/j.tranon.2020.100874 (2020).
Spoerke, J. M. et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin. Cancer Res. 18, 6771–6783. https://doi.org/10.1158/1078-0432.Ccr-12-2347 (2012).
Lee, Y. W. et al. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project. Cancer Res Treat. 53, 123–130. https://doi.org/10.4143/crt.2020.559 (2021)

Table 1. Characteristics of patients

	Dose level 0 Alpelisib 200mg + Capeciabine 1000mg/m² (n=3)	Dose level 1 Alpelisib 300mg + Capeciabine 1000mg/m² (n=6)		Dose level 2 Alpelisib 300mg + Capeciabine 1250mg/m² (n=3)	Total (n = 12)
Age	50.7 (49-53)	54.5 (33-69)		55.0 (40-63)	53.7 (33-69)
Gender
Male Female	0 (0) 3 (100)	1 (17) 5 (83)		1 (33) 2 (67)	2 (17) 10 (83)
ECOG PS 0 1 Diagnosis Breast Colorectal	0 (0) 3 (100) 2 (67) 1 (33)	0 (0) 6 (100) 3 (50) 3 (50)		0 (0) 3 (100) 1 (33) 2 (67)	0 (0) 12 (100) 6 (50) 6 (50)
No. of metastatic sites
1	0 (0)	3 (50)		1 (33)	4 (33)
2	1 (33)	1 (17)		1 (33)	3 (25)
More than 2	2 (67)	2 (33)		1 (33)	5 (42)
Prior anticancer treatment
Surgery Radiotherapy Chemotherapy	3 (100) 3 (100) 3 (100)	6 (100) 3 (50) 6 (100)		3 (100) 1 (33) 3 (100)	12 (100) 7 (58) 12 (100)
Prior chemotherapy regimens, n
≤2	2 (67)	2 (33)	3 (100)		7 (58)
3-4	1 (33)	2 (33)	0 (0)		3 (25)
≥5	0	2 (33)	0 (0)		2 (17)

Data are frequency (percentage) or mean (range). ECOG PS, Eastern Cooperative Oncology Group performance status

Table 2. Clinical summary of patients

Dose level

Age

Sex

Diagnosis

Site of Metastatic Disease

Prior Systemic Therapies

PIK3CA mutation status

Other pathogenic variants

Best response

PFS

(months)

Survival

S0001
S0002

S0003

S0004

S0005

S0006

S0007

S0008
S0009

S0010

S0011

S0012

0

1

2

49

50

53

55

61

69

33

59

50

63

40

62

F

M

F

M

F

Breast ca

CRC

Breast ca

CRC

Breast ca

CRC

Breast ca

CRC

Bone, peritoneum

Skin, pleura, LNs

Lung, liver, peritoneum, LNs

Bone, adrenal, LNs

Bone

Lung, liver, peritoneum, bone

Bone, liver

Liver

Lung, liver

Lung

Lung, liver, pleura

2

3

2

3

2

5

13

4

2

H1047L

E545K

-

E545K, E726K

-

E545K

H1047R

G118D

-

N345K

E542K

PTEN PTCH1 CDH1

KRAS

APC TP53 SMAD4

CDH1 AR

KRAS

KRAS TP53 PTEN

TP53

KRAS APC

PR

PD

SD

PD

SD

PD

PR

PD

26.5

3.5

1.1

1.4

19.6

0.9

2.8

2.5

0.9

1.4

7.5

2.6

Survival

Death

Death Death

Survival

Death Death

Death

Survival

Death

Data are frequency (percentage); ca, cancer; CRC, colorectal cancer; LNs, lymph nodes; NGS, next generation sequencing; PFS, progression free survival; PR, partial response; SD, stable disease; PD, progression disease.

Table 3. Treatment-related adverse events

	Dose level 0 (n=3)		Dose level 1 (n=6)		Dose level 2 (n=3)		Total (n=12)
Adverse event	All Gr	Gr 3-5	All Gr	Gr 3-5	All Gr	Gr 3-5	All Gr	Gr 3-5
Dermatologic
Hand-foot SD	1	0	2	0	2	0	5	0
Skin rash	1	0	0	0	0	0	1	0
Constitutional
Fatigue	1	0	1	0	0	0	2	0
Weakness	0	0	1	1	1	0	2	1
Weight loss	0	0	0	0	1	0	1	0
Gastrointestinal
Diarrhea	1	0	4	0	1	0	6	0
Anorexia	1	0	2	0	2	0	5	0
Nausea	2	0	4	2	3	2	9	4
GB perforation	1	1	0	0	0	0	1	1
Pulmonary
Pleural effusion	1	0	0	0	0	0	1	0
Pain	1	0	0	0	0	0	1	0
Neurology
Sensory neuropathy	1	0	0	0	2	0	3	0
Mucositis	0	0	2	0	2	0	4	0
Infection
Cystitis	1	0	0	0	0	0	1	0
Oral candidiasis	0	0	0	0	1	0	1	0
Depression	1	0	0	0	0	0	1	0
Hematology
Anemia	1	0	2	0	1	0	4	0
Thrombocytopenia	0	0	0	0	0	0	0	0
Neutropenia	0	0	2	1	0	0	2	1
Chemistry
Hyperglycemia	2	0	4	1	3	1	9	2
AST increased	0	0	1	0	0	0	1	0
Hyperbilirubinemia	2	0	2	1	2	1	6	2

Data are frequency; SD, syndrome; GB, gall bladder; AST, Aspartate transaminase

Table 4. Pharmacokinetics parameters of alpelisib and capecitabine

	Dose level 0 Alpelisib 200mg + Capeciabine 1000mg/m² (n=3)	Dose level 1 Alpelisib 300mg + Capeciabine 1000mg/m² (n=6)	Dose level 2 Alpelisib 300mg + Capeciabine 1250mg/m² (n=3)
Alpelisib
c_max t_max	1167.8 (844.7-1699.7) 2 ± 0.6	1235.3 (705.6-1963.3) 4 ± 1.8	2035.6 (942.4-3567.1) 4 ± 2.1
AUC_0-6h	4930.5 (3201.5-6991.2)	5068.9 (2006.4-8978.1)	8192.2 (2924.5-15893.9)
t_1/2	6.5 (3.65-10.9)	9.29 (4.1-14.5)	4.3 (4.3-NC)
Capecitabine
c_max t_max	2498.0 (1135.0-4907.7) 1.0 ± 0.0	4159.0 (1925.9-7980.2) 2.0 ± 1.9	7004.5 (746.0-18227.9) 1 ± 0.0
AUC_0-6h	2674.4 (1175.2-5310.2)	5995.5 (3471.4-10874.7)	8710.8 (858.2-22483.8)
t_1/2	0.89 (0.89-NC)	0.63 (0.44-0.89)	0.73 (0.39-1.31)

Data are mean (range) and SD. cmax, peak plasma concentration; t_max, time to reach peak plasma concentration; AUC, area under the concentration-time-curve; t_1/2, half-life of time; NC: Not calculated. AUC: ng·h/mL, Cmax: ng/mL, t_max & t_1/2: hour.

No competing interests reported.

SCSupplementarydataALCAP.docx

Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors

Status:

Version 1

Abstract

Figures

Introduction

Results

Discussion

Material and methods

Declarations

References

Tables

Additional Declarations

Supplementary Files

Status:

Version 1